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Abstract 25 
Background: The beneficial effects of selenium (Se) to human health are exerted by 26 
selenoproteins, which can be quantified in blood and used as biomarkers of Se status. 27 
Different responses of Se biomarkers after supplementation with selenomethionine and 28 
sodium selenite have been observed and some of them could be due to genetic 29 
polymorphisms, mainly single nucleotide polymorphisms (SNPs). Brazil nuts are 30 
known to be the richest natural source of Se. Objective: Investigate how genetic 31 
variations in selenoprotein genes modulate biomarkers of Se status in response to Brazil 32 
nut supplementation. Methods: The SU.BRA.NUT study was a four month 33 
interventional trial which involved healthy volunteers of both genders, selected in 34 
University of Sao Paulo. The supplementation was done with one Brazil nut a day for 8 35 
weeks, followed by 8 weeks of washout. Blood samples were collected at 5 time points: 36 
baseline, 4 and 8 weeks of supplementation and 4 and 8 weeks of washout for analysis 37 
of five biomarkers of Se status – erythrocyte GPx1 (Glutathione Peroxidase 1) activity, 38 
plasma GPx3 activity, plasma Se, erythrocyte Se, and plasma selenoprotein P. The gene 39 
expression of GPX1, SELENOP, SELENOF and SELENOS was done before and after 8 40 
weeks of supplementation. The volunteers were genotyped for SNPs in GPX1 41 
(rs1050450, rs3811699 and rs1800699), GPX4 (rs713041), SELENOP (rs3877899 and 42 
rs7579), SELENOF (rs5845) and SELENOS (rs34713741). Results: A total of 130 43 
volunteers finished the protocol. The concentrations of four biomarkers of Se status 44 
increased significantly after 4 and 8 weeks of supplementation, being modulated by 45 
gender. In addition, erythrocyte GPx1 activity was associated with rs1050450, rs713041 46 
and rs5845. Plasma Se was associated with rs7579 and selenoprotein P with plasma Se 47 
at baseline. Nut supplementation significantly increased GPX1 mRNA expression only 48 
in subjects with CC genotype at rs1050450. SELENOP mRNA expression was 49 
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significantly lower in subjects with GG genotype at rs7579 before and after 50 
supplementation.  Conclusion: Genetic variations in GPX1 and SELENOP genes are 51 
associated with different responses of molecular and biochemical biomarkers of Se 52 
status after Brazil nut supplementation in healthy Brazilians. The SU.BRA.NUT study 53 
was registred at www.clinicaltrials.gov as NCT 03111355. 54 
Keywords: Glutathione Peroxidase, SNPs, selenium, polymorphisms, nutrigenetics 55 
Abbreviations 56 
 Se, Selenium; Sec, selenocysteine; SNP, single nucleotide polymorphisms; GPx,  57 
glutathione peroxidase enzyme; GPX1, cytosolic glutathione peroxidase gene or 58 
erythrocyte glutathione peroxidase gene  ; GPX3, plasma glutathione peroxidase gene ; 59 
GPX4, phospholipid glutathione peroxidase gene; SELENOP, Selenoprotein P gene; 60 
SELENOS, Selenoprotein S gene;  SELENOF, Selenoprotein 15 gene;  SePP, 61 
Selenoprotein P protein;  SU.BRA.NUT, Supplementation with Brazil Nuts study. 62 
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INTRODUCTION 70 
 The regular intake of nuts has been proposed to decrease risk for chronic diseases 71 
such as cancer, cardiovascular disease and type 2 diabetes 1–4. Brazil nuts (Bertholletia 72 
excelsa, family Lecythidaceae) are known to be the richest source of selenium (Se), an 73 
essential micronutrient for human health. The main form of Se in Brazil nuts are 74 
selenomethionine 5.  Se is incorporated as the amino acid selenocysteine (Sec) during 75 
translation into 25 selenoproteins encoded by the human genome, many of which show 76 
a wide range of functions, including antioxidant defense, redox function, thyroid 77 
hormone metabolism, immune function, reproduction and fertility 6,7. 78 
Low Se status has been associated with increased risk for several diseases, such 79 
as cancer, cardiovascular disease, viral infections, male infertility and inflammatory 80 
disorders 7. Potentially, genetic variations could modulate this risk by affecting 81 
responses to Se intake 8. Several studies have demonstrated that polymorphisms in 82 
genes encoding selenoproteins have functional consequences 9. For instance, the 83 
rs1050450 (Pro198Leu) in GPX1 (Glutathione Peroxidase 1) gene was associated with 84 
lower erythrocyte GPx1 activity 10,11 and lower plasma Se in humans 12.  Although the 85 
regulation of selenoproteins expression is mainly during translation, the mRNA 86 
expression of selenoproteins, such as SELENOF (Selenoprotein 15), SELENOK and 87 
SEPHS1 can be altered by Se status, as shown previously 13.  Nevertheless, human 88 
studies have failed to demonstrate an association between Se status and selenoprotein 89 
transcripts 14–16. Only three studies have observed a positive association between Se 90 
supplementation and increased selenoprotein expression in humans (SELENOF, 91 
SELENOK, GPX1 and SELENOP) 13,17,18. 92 
Glutathione peroxidase 1 (GPx1) activity is sensitive to alterations in Se status in 93 
individuals with low to moderate intake 19. The GPX1 gene contains a single nucleotide 94 
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polymorphism (SNP) in the coding region, which causes a Proline to Leucine amino 95 
acid change at position 198 (rs1050450) 20. This variation has been associated with 96 
increased risk for lung, breast, prostate and bladder cancers 11,21–23  and  has been found 97 
to modulate the response to Se supplementation in healthy subjects 12,24.  Carriers of the 98 
minor allele T had lower plasma Se at baseline and after one year of supplementation 99 
with selenomethionine they had increased urinary Se excretion 12,24. Glutathione 100 
peroxidase 4 (GPx4) is the only GPx that can reduce phospholipid hydroperoxides in 101 
cell membranes 25. There is a C>T substitution located in the 3’UTR of the GPX4 gene 102 
(rs713041) and this variant affects Se incorporation in cell culture models 26 and the 103 
response to Se supplementation in healthy adults 27. It was demonstrated that subjects 104 
with the TT genotype had lower GPx3 activity after 6 weeks of supplementation with 105 
sodium selenite and lower GPx4 activity during the washout period. Also, females with 106 
the TT genotype had lower GPx1 and TR1 concentration during the supplementation 107 
and the washout period 27.  108 
Selenoprotein P (SELENOP) is the major component of blood Se and the key Se 109 
transporter in the body 28. Two SNPs with functional consequences are present in this 110 
gene; one G>A substitution in the coding region causes an amino acid substitution 111 
Alanine to Threonine at position 234 of the protein (rs3877899), and the other G>A 112 
substitution is located in the 3’UTR, important for Sec insertion (rs7579). Both SNPs 113 
modulate the response to Se supplementation in healthy adults 8. It was demonstrated 114 
that carriers of the minor allele A for both SNPs had higher SePP concentrations after 115 
supplementation. Also, males with the AA genotype for rs7579 had lower GPx3 activity 116 
after supplementation and during the washout period compared with males with the GG 117 
genotype 8. Selenoprotein S (SELENOS) is an endoplasmic reticulum (ER) 118 
selenoprotein involved in protecting ER from stress caused by misfolded proteins 29. A 119 
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C>T substitution located in the promoter region of the gene (rs34713741) has been 120 
associated with increased risk for rectal cancer 30. Selenoprotein 15 (SELENOF) is 121 
another selenoprotein involved in maintaining ER integrity 31.  A SNP in the 3’UTR of 122 
this gene, a G>A substitution in position 1125 (rs5845), has been associated with 123 
increased risk for rectal cancer 30 and lung cancer 32.  124 
Most of the studies investigating the effect of Se supplementation on biomarkers 125 
of Se status were conducted using different chemical forms of selenium in different 126 
concentrations 8,12,27,33,34. The studies with Brazil nut supplementation were conducted 127 
only in specific groups of the population and considered mainly three SNPS in 128 
selenoproteins (rs1050450, rs3877899 and rs7579) genes with just three biomarkers 129 
evaluated before and after supplementation. No study was conducted in healthy 130 
Brazilians using other functional SNPs in selenoproteins, other plasma biomarkers and 131 
evaluated the washout period to investigate how the biomarkers return after 132 
supplementation withdraw.  Therefore, this study was conducted to evaluate if the six 133 
functional polymorphisms in selenoprotein genes modulate the response of biomarkers 134 
of Se status, on both molecular and biochemical levels, during supplementation with 135 
Brazil nuts and the washout period in healthy Brazilians.    136 
 137 
SUBJECT AND METHODS 138 
Study population and supplementation protocol 139 
The present study involved 130 unrelated healthy volunteers selected at 140 
University of Sao Paulo who took part of the Supplementation with Brazil Nuts study 141 
(SU.BRA.NUT) described previously 35.  Subjects were excluded if they were pregnant, 142 
younger than 20y and older than 60y taking multivitamins and mineral supplements, 143 
anti-inflammatory drugs, with excessive alcohol consumption, athletes, with chronic 144 
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diseases such as cancer, diabetes, and cardiovascular disease and obese (BMI > 35). At 145 
the beginning of the study (baseline), 20 mL venous blood samples were drawn and the  146 
volunteers received. plastic bottles with nuts enough for four weeks. They were oriented 147 
to take a daily supplement of one Brazil nut a day with a meal. At the end of four weeks 148 
of supplementation, they returned and received another plastic bottle with nuts for the 149 
last four weeks. At the end of four (4-week-intervention) and eight weeks (8-week 150 
intervention) of supplementation, another 20 mL blood sample was taken, and then two 151 
more blood samples were taken after a further four (4-week washout) and eight weeks 152 
without intervention (8-week washout) . Volunteers were asked to complete a control 153 
calendar and mark with an “x” when they consumed each nut throughout the 154 
intervention period.  Written informed consent was obtained from all volunteers before 155 
blood sampling. The protocol was approved by Faculty of Pharmaceutical Sciences 156 
Ethical Committee (CAE: 00961112.3.0000.0067) and was conducted according to the 157 
Helsinki Declaration. The SU.BRA.NUT study was registred at clinicaltrials.gov as 158 
NCT 03111355. 159 
Composition and Se content of Brazil nuts  160 
The Se content of a random sample of Brazil nuts representative of the four 161 
batches used in the study was analyzed using hydride generation flame atomic 162 
absorption spectrometry as described previously 36 and the centesimal composition was 163 
done as proposed by the Association of Official Analytical Chemists 37.  164 
 165 
Sample collection 166 
Fasting blood samples (20 mL) were drawn by venipuncture into four 5 mL 167 
EDTA tubes for quantification of the five biomarkers of Se status. An aliquot of 1.5 mL 168 
of whole blood from one EDTA tube was stored into 1,5mL sterile plastic tubes used 169 
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for DNA extraction and subsequent genotyping, and an aliquot of 500 µL of whole 170 
blood from the same EDTA tube was stored into 1,5mL sterile plastic tubes used for 171 
RNA extraction and subsequent gene expression. Another 5mL of blood were collected 172 
in a tube without anticoagulant to obtain serum for determination of the lipid profile 173 
which was described previously 35. The total volume of blood samples collected was 174 
25mL. Plasma was separated by centrifugation at 3,000 rpm for 15 min at 4 °C. The 175 
erythrocyte pellet was washed three times with 5 mL sterile 9 g/L NaCl solution, slowly 176 
mixed by inversion, and centrifuged at 10,000 rpm for 10 min (Eppendorf, C5408) at 4 177 
°C, and the supernatant fluid was discarded. Aliquots of whole blood, plasma and 178 
erythrocytes were frozen at -80 °C in sterile, demineralized tubes until the analyses 179 
were performed. 180 
Biomarkers of Se status 181 
Plasma Se and erythrocyte Se concentrations were determined by inductively 182 
coupled plasma mass spectrometry (ICP-MS, Perkin Elmer DRC II) as described 183 
previously 38. Samples were diluted 1:50 into a 15 mL polypropylene tube with a 184 
solution containing 0.01% (v/v) Triton X-100, 0.5% (v/v) nitric acid and 10 µg/L of 185 
each one of the internal standards. The certified reference material Seronorm Trace 186 
Elements Serum (SERO AS, Billingstad, Norway) was used for the quality control 187 
assessment. Erythrocyte GPx activity was determined using commercial kit (Randox, 188 
Labtest, Minas Gerais, Brazil) according to manufacturer’s instructions. The enzyme 189 
activity was evaluated spectrophotometrically at 37 °C at 340 nm using an automated 190 
biochemical analyzer Labmax 240 (Labtest, Minas Gerais, Brazil). Hemoglobin (Hb) 191 
concentration was also determined spectrophotometrically in order to express 192 
erythrocyte GPx activity in U/g Hb. Plasma GPx (GPx3) activity was calculated by the 193 
method of Paglia and Valentine (1967), as modified previously 39, using hydrogen 194 
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peroxide as a substrate. One unit of GPx3 activity is defined as that which oxidizes 1 195 
μmol NADPH/min. SePP concentration was determined in plasma using an in-house 196 
SePP ELISA (Enzyme Liked Immunosorbent Assay) assays as described previously 40 197 
using a 96-well microplate reader (FLUOstar Omega microplate reader, BMG Labtech, 198 
Ortenberg, Germany). Each sample was analyzed in duplicate with aliquots of purified 199 
SePP incubated alongside (range 0.25–16 ng/well) acting as the standard curve. A 200 
pooled plasma from a previous study conducted at The Rowett Institute was used as a 201 
quality control. 202 
Genotyping 203 
Total genomic DNA was extracted from whole blood using the Purelink 204 
Genomic DNA Minikit (Invitrogen, Thermo Scientific, CA, USA) and the final 205 
concentration and purity were measured by spectrophotometry at 260 and 280 nm 206 
(NanoDrop ND 1000 Thermo Scientific, Wilmington, DE, USA). Genotyping was 207 
carried out by real-time PCR using the StepOne Plus Real-Time system with Taqman 208 
SNP Genotyping Assays (Applied Biosystems, Thermo Scientific, Foster City, CA, 209 
USA). The allelic discrimination was obtained by performing an endpoint read. The 210 
SNPs selected were located in GPX1 gene (rs1050450, rs3811699 and rs1800668), 211 
GPX4 gene (rs713041), SELENOP gene (rs3877899 and rs7579), SELENOS gene 212 
(rs34713741) and SELENOF gene (rs5845).  213 
Selenoprotein gene expression 214 
 Total RNA was extracted from whole blood using the Ribopure Blood Kit 215 
(Ambion, Thermo Scientific, Austin, TX, USA) and final concentration was measured 216 
in a NanoDrop ND 1000 spectrophotometer (NanoDrop ND 1000, Thermo Scientific, 217 
Wilmington, DE, USA). cDNA was synthesized by reverse transcription PCR using the 218 
High Capacity Reverse Transcriptase kit (Applied Biosystems, Thermo Scientific, 219 
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Foster City, CA, USA). Analysis of gene expression was performed by real-time 220 
quantitative PCR (qPCR) in the QuantStudio 12K Real Time PCR System using 221 
Taqman Gene expression Assays for GPX1, SELENOP, SELENOS and SELENOF  222 
(Applied Biosystems, Thermo Scientific, Foster City, CA, USA). GPX4 mRNA 223 
expression was not evaluated because the literature states that this protein is ranked high 224 
in the hierarchy of selenoprotein expression with no predictable changes in gene 225 
expression after supplementation. Glyceraldehyde phosphate dehydrogenase (GAPDH) 226 
mRNA expression was used as a reference gene. Relative gene expression was 227 
calculated based on the  2-∆∆ Cq method 41. 228 
 229 
Statistical Analysis 230 
 Continuous variables were tested for normality using the Kolmogorov–Smirnov 231 
test. The data were presented as geometric means (CI 95%). Concentrations of the five 232 
biomarkers were compared in the different time points using ANOVA repeated 233 
measures or Friedman’s test. The percentage of variation for each biomarker was 234 
calculated considering the time point immediate before, for example, the percentage of 235 
variation for GPx1 activity at 4weeks of nuts was calculated using the formula: 236 (GPx1 activity 4w ) – (GPx1 activity baseline  )  ∗ 100(GPx1 activity baseline  )  
The variables used for multiple linear regressions in table 5 were done 237 
considering only 3 time points: baseline, 8 weeks of nuts and 8 weeks of washout. 238 
Therefore, change 1 was referring to the entire supplementation period (baseline until 8 239 
weeks of nuts) and change 2 to the washout period (8 weeks of nuts until 8 weeks of 240 
washout. For example the variable “Change1_GPx1” was calculated using the formula:  241 (GPx1 activity 8w ) – (GPx1 activity baseline  )  ∗ 100(GPx1 activity baseline  )  
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A genetic dominant model was used to evaluate differences in the presence of 242 
the rare allele. In this model, individuals with the rare allele were combined together in 243 
one category, leaving the common genotype in another category. Multiple linear 244 
regression models were created using the biomarkers at each time of intervention as 245 
response variables. Age, body fat percentage, gender, plasma Se, erythrocyte Se and six 246 
SNPs were included as predictors. Only six SNPs were used because the three SNPs in 247 
GPX1 gene were in linkage disequilibrium with an r = 1 and D’> 0,5. Repeated 248 
measures analysis of covariance (ANCOVA) was performed to investigate the effect of 249 
the genotypes for SNPs appointed in the linear regression models. The Chi-square test 250 
with continuity correction was used to determine whether genotype frequencies 251 
followed the Hardy-Weinberg Equilibrium. The haplotype distribution and linkage 252 
disequilibrium analysis were done in the software Haploview 4.2. SNPs were 253 
considered in linkage disequilibrium when D’> 0,5. Differences were considered 254 
significant at P < 0.05. The analyses were performed using the Statistical Package for 255 
the Social Sciences software version 17.0 for Windows (SPSS, Chicago, IL, USA) and 256 
GraphPad Prism (GraphPad Prism version 5.00 for Windows, GraphPad Software, San 257 
Diego, CA, USA). 258 
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RESULTS 259 
 A total of 135 adults were enrolled in the study during 2013 and started the 260 
supplementation. Of these, 2 females stopped the supplementation complaining of side 261 
effects (ex. sickness), leaving 133 subjects that finished the 8 weeks of intervention. Of 262 
these 133 volunteers, 2 males withdraw during the first month of washout and one male 263 
during the second month, leaving a total of 130 volunteers that finished the entire 264 
protocol. 265 
 266 
Characteristics of the volunteers and nut composition 267 
The characteristics of the volunteers are summarized in Table 1. Mean age was 268 
29.8 ± 9.2 y and mean BMI was 23.3 ± 3.3 kg/m2. There was a 100% adherence to the 269 
supplementation confirmed by the control calendar given at baseline, the empty plastic 270 
bottles at the end of supplementation and the increase of three times in plasma Se after 8 271 
weeks of supplementation with Brazil nuts. The Se content and centesimal composition 272 
of Brazil nuts are shown in Table S1. Four different batches were used during the 273 
supplementation. The mean ± standard deviation for Se content of these four batches 274 
was 100.4 ± 5.3 µg/g. The average weight of the nuts ranged from 3g to 4g, therefore 275 
each nut provided from 300 µg of Se to 400 µg of Se, which is approximately six times 276 
higher than the RDA (Recommended Dietary Allowances) for adults (55µg/d). 277 
 278 
Effect of Brazil nut supplementation on five biomarkers of Se status 279 
 The concentrations of the five biomarkers of Se status measured during nut 280 
supplementation and washout period are shown in Table 2. GPx1 activity decreased 281 
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significantly after 4 weeks of supplementation, increased by 8 weeks of 282 
supplementation (P < 0.001) and remained high during the first 4 weeks of Brazil nut 283 
withdrawal; it finally decreased after 8 weeks washout (P = 0.004). Erythrocyte Se 284 
concentrations increased after 4 and 8 weeks intervention and decreased after 8 weeks 285 
washout (P < 0.001).There was a significant increase in GPx3 activity after 4 weeks of 286 
supplementation (P = 0.004). Similarly, plasma Se concentrations increased 287 
significantly after 4 and 8 weeks of supplementation (P < 0.001). During the washout 288 
period, there was a sharp decrease in plasma Se compared to 8 weeks of 289 
Brazil nut intake (P < 0.001). The concentrations of plasma SePP were also increased 290 
after the supplementation and reduced after nut withdrawal (P = 0.001). The percentage 291 
of the variation for each biomarker during the supplementation and the washout period 292 
is shown in Figure 1. 293 
Genotypes and haplotypes in selenoprotein genes 294 
Genotype and allele frequencies of SNPs in selenoprotein genes are shown in Table 3. 295 
All SNPs were in Hardy-Weinberg Equilibrium. Haplotype analyses showed evidence 296 
of linkage disequilibrium for SNPs in GPX1 gene: rs1050450 x rs1800668 (D’= 1.0 and 297 
r2= 0.98) and rs1050450 x rs3811699 (D’= 1.0 and r2= 1.0).  In fact, in Table 3 the 298 
genotypes frequencies of the three SNPs are exactly the same. Only two haplotypes 299 
were observed, the common haplotype CCG for rs1050450, 1800668 and rs3811699 300 
with a frequency of 74% and the rare haplotype TTA with 25%. Therefore, only 301 
rs1050450 was used for further analysis. For the SNPs in the GPX4, SELENOF and 302 
SELENOS genes, the frequency of the rare genotypes was between 19% and 8%. No 303 
haplotype analysis was performed in those genes because only one SNP was genotyped 304 
in each gene.Variables influencing biomarkers of Se status during Brazil nut 305 
supplementation and washout period 306 
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    Multiple linear regression models for the five biomarkers of Se status in each time 307 
point of the protocol are shown in Table 4. GPx1 activity was associated with 308 
rs1050450 after 4 (P = 0.037) and 8 weeks (P = 0.017) of intervention and with rs5845 309 
after 4 weeks (P = 0.003) of intervention with both SNPs reducing GPx1 activity. After 310 
8 weeks of washout, GPx1 activity was associated with rs5845 in SELENOF, which was 311 
lower in the presence of the rare allele A (P = 0.049) and with rs713041 in GPX4, 312 
which increased GPx1 activity in individuals carrying the rare allele T (P = 0.036). The 313 
SNP rs713041 in GPX4 gene was associated with Erythrocyte Se concentrations at 314 
baseline, reducing its concentrations in the presence of the rare allele T (P = 0.038).  315 
 Plasma Se concentration was associated with rs7579 in SELENOP (P = 0.034) 316 
and rs34713741 in SELENOS (P = 0.038) after 4 weeks of supplementation, which was 317 
lower in the presence of the rare allele for both SNPs.  Plasma SePP concentrations 318 
were positively associated with plasma Se at baseline and GPx3 activity was positively 319 
associated with plasma Se after 4 (P = 0.050) and 8 weeks (P = 0.025) of 320 
supplementation, as expected due to the same blood compartment location of both 321 
biomarkers (Table 4).  A complete table of the biomarkers stratified by all functional 322 
SNPs can be seen at Supplementary table 2 (Table S2).  323 
Erythrocyte GPx1 activity was stratified by rs1050450, as appointed in the 324 
multivariate regression analysis (Figure 2). During the intervention, GPx1 activity was 325 
lower in carriers of the rare allele T (CT+TT), almost reaching statistical significance at 326 
4 weeks of supplementation (P = 0.057, Figure 2a). SePP concentrations were stratified 327 
by rs7579 (Figure 2b).  At baseline, SePP concentrations were higher for carriers of the 328 
rare allele A, when the interaction with gender was considered (P = 0.048).  329 
The percentage of variation on the concentrations of biomarkers of Se status is 330 
shown in Table 5. The difference in GPx1 activity comparing baseline and 8 weeks of 331 
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supplementation (Change1_GPx1) was associated with rs7579 in SELENOP (P = 0.044) 332 
and with rs5845 (P < 0.001), in which the presence of the rare allele increased this 333 
difference, meaning that the values were higher for carriers of the rare allele A after 8 334 
weeks of supplementation. The difference in Erythrocyte Se concentrations during the 335 
supplementation (Change1_ Erythrocyte Se) was associated with rs34713741 in 336 
SELENOS (P = 0.010), in which the presence of the rare allele T also increased this 337 
difference. BMI and gender had a negative effect on the variation in Erythrocyte Se, in 338 
which individuals with higher BMI and females had higher values at baseline. The 339 
change in GPx3 activity in response to the supplementation (Change1_ GPx3 activity) 340 
was negatively associated with rs5845 in SELENOF (P = 0.014), in which carriers of 341 
the rare allele A had higher GPx3 activity at baseline. However, interaction with BMI 342 
increased the variation (P = 0.011). The only two variables affecting the variation in 343 
Plasma Se were gender and BMI, both having a negative effect. The difference in GPx1 344 
activity comparing 8 weeks of washout and 8 weeks of supplementation 345 
(Change2_GPx1) was negatively associated with gender, in which females had higher 346 
GPx1 activity after 8 weeks of supplementation. However, the interaction with 347 
rs713041 had the opposite effect: females carriers of the variant allele T had higher 348 
GPx1 activity at 8 weeks of washout. Finally, the difference in SePP concentrations 349 
comparing 8 weeks of washout and 8 weeks of supplementation (Change2_SePP) was 350 
negatively associated with rs5845 in SELENOF gene, in which carriers of the rare allele 351 
A had higher SePP concentrations after supplementation (Table 5). 352 
Effect of Brazil nut supplementation on mRNA expression of selenoprotein genes 353 
Gene expression of four selenoprotein genes (GPX1, SELENOP, SELENOS and 354 
SELENOF) was analyzed on previously genotyped volunteers before and after 8 weeks 355 
of Brazil nut supplementation. The results are shown in Figure 3. GPX1 mRNA 356 
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expression increased after supplementation in individuals with the CC genotype for 357 
rs1050450 (P = 0.026) while it did not change for carriers of the T allele (Figure 3a). 358 
Consequently, after Brazil nut supplementation, GPX1 mRNA expression was lower in 359 
individuals with the CT and TT genotypes compared to the CC group (P < 0.05). 360 
SELENOP mRNA expression was higher in carriers of the rare allele A for rs7579 361 
either before or after supplementation (Figure 3b, P < 0.05), and nut supplementation 362 
did not significantly changed SELENOP mRNA expression whatever the genotype 363 
group. No effect of genotypes on SELENOF and SELENOS mRNA expression was 364 
observed either before or after the supplementation (Figure 3c and 3d). 365 
DISCUSSION 366 
 The influence of genetic variants on the response to Se supplementation have 367 
been proposed before 8,12,27,34. Our results not only confirm these earlier observations, 368 
but also extend them by demonstrating that the rs5845 in SELENOF gene modulated 369 
erythrocyte GPx1 activity, the variation of GPx1, GPx3 activity after supplementation 370 
and the variation on SePP after nut withdraw. This study is the first to report this 371 
unexpected association between rs5845 in SELENOF and Se biomarkers after 372 
supplementation with Brazil nuts, the first to use SePP concentrations as a biomarker of 373 
Se status in Brazilians and the first to measure all five biomarkers during the washout 374 
period. Moreover, this study demonstrated that Brazil nut supplementation was effective 375 
in increasing mRNA expression of GPX1 and SELENOP and that this effect was 376 
modulated by functional polymorphisms on those genes.  377 
  It was observed a delayed response of the two erythrocyte biomarkers of Se 378 
status to Brazil nut supplementation, with values increasing up to the first four weeks of 379 
the washout period. This apparently slow response could be explained by erythrocytes 380 
having a lifespan of 120 days so that it takes time for changes in selenoprotein synthesis 381 
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to appear in the mature red cell population 42,43. This is the first study to use plasma 382 
SePP concentrations as a biomarker of Se status in healthy Brazilians. The baseline 383 
plasma Se concentration of 96.7 µg/L (1.22 µmol/L) would be expected to maximize 384 
plasma GPx activity, but not SePP concentration since earlier work has shown that the 385 
plasma Se concentration needed to maximize GPx3 activity is about 90 µg/L 44 and to 386 
maximize plasma SePP concentration it is approximately 120 µg/L 45. As a result, the 387 
studied population could be considered to have a moderate to adequate Se status which 388 
was able to respond to Se supplementation with an increase in concentrations of plasma 389 
Se and SePP 43,46. We suggest that the threshold for maximize GPx3 activity be 390 
reviewed, as our work demonstrated that this population with a baseline plasma Se of 391 
90µL/L had a significant increase in GPx3 activity after 4 weeks of supplementation. 392 
In our study subjects with the rare allele T for rs1050450 in GPX1 gene had 393 
lower GPx1 activity. This observation is consistent with previous studies 10,11,47,48. It is 394 
hypothesized that the change of the amino acid Proline to Leucine alters the secondary 395 
structure of the protein, which can have profound effects on its activity and stability 21. 396 
This was confirmed by in vitro studies where Se supplementation reduced enzyme 397 
thermostability for the Leu-variant 49. It was observed that the SNPs rs1050450, 398 
rs3811699 and rs1800668 were in linkage disequilibrium. This linkage was also 399 
observed in a Japanese study conducted with type 2 diabetic patients 10. One possible 400 
explanation for the reduced GPx1 activity is that the presence of these three genetic 401 
variations affected the transcriptional process and, as a result, the final enzyme activity 402 
was lower. Moreover, in our work, the Brazil nut supplementation was effective in 403 
increase GPX1 mRNA expression in whole blood, only in individuals with the CC 404 
genotype at rs1050450. Previous studies did not find a positive association of Se 405 
supplementation and selenoprotein gene expression 14–16, however, three studies confirm 406 
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our results 13,17,18 . Differences may be explained by the lack of the genotype analysis on 407 
previous studies, maybe to observe this effect of Se supplementation on mRNA levels 408 
of GPX1 is necessary to stratify by genotypes.  409 
The presence of rs7579 in the SELENOP gene influenced not only SePP plasma 410 
concentrations but also SELENOP mRNA expression. SePP protein concentrations were 411 
higher at baseline in carriers of the variant allele A for this 3’UTR SNP. Furthermore, 412 
A-carriers had higher SELENOP mRNA levels than GG at baseline and after 413 
supplementation. Previous work with humans have not found an association between Se 414 
supplementation and SELENOP mRNA expression in white blood cells 14,16. It should 415 
be noted that the present work used whole blood for the mRNA expression. Only one 416 
study found a positive association by showing that rs7579 influenced SELENOP mRNA 417 
expression 17. The SePP protein has two isoforms in plasma, the 50kDa and the 60kDa, 418 
that are influenced by the genotype for both SNPs in SELENOP gene. Individuals with 419 
the GA genotype for rs3877899 had a lower proportion of the SePP 60kD, with the Sec-420 
rich domain  50. This difference in the proportion of SePP isoforms may affect Se 421 
availability in plasma for selenoprotein synthesis in different tissues.   422 
The 3’UTR region of SELENOF gene has two SNPs which are in the same 423 
haplotype. The first one is a located a C>T substitution at position 811 (rs5859) and the 424 
other is a G>A substitution at position 1125 (rs5845). The two possible haplotypes are 425 
811C/1125G or 811T/1125A 51. Previous work has demonstrated that the SECIS 426 
element containing the A variant is less responsive to Se supplementation and may 427 
influence the translation of Selenoprotein 15 protein 52. Two biomarkers of Se status 428 
were associated with rs5845 in SELENOF gene in our study: erythrocyte Se 429 
concentrations and GPx1 activity. We also observed that this SNP modulated the 430 
percentage of variation of GPx1 and GPx3 activities after supplementation and the 431 
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variation in SePP during washout period. To our knowledge, this is the first time that 432 
rs5845 is associated with these biomarkers. These were unexpected associations, since 433 
the SNP is located in the SELENOF gene and the biological effect was observed in 434 
other selenoproteins.  However, the biological function of the Selenoprotein 15 is still 435 
unknown and maybe the hierarchy of selenoprotein expression may help explain these 436 
associations with other selenoproteins. 437 
This study has several limitations. The first one is the small sample size, which 438 
could have masked significant associations of the genotypes with the biomarkers. The 439 
second one is the absence of a control group, however, since the main goal of this 440 
before-after interventional trial was to investigate the effect of the genotypes on the 441 
response to the dietary intervention, we decided that each person before 442 
supplementation would be a better control. The other limitation is the small number of 443 
males in the study group which could have biased the gender effect in the statistical 444 
modeling. 445 
 In summary, the results of this study suggest that genetic variants in 446 
selenoprotein genes and gender influence the response of plasma and erythrocyte 447 
biomarkers of Se status to a daily supplementation with one unit of Brazil nut in healthy 448 
adults in Brazil. Furthermore, the genotypes for rs1050450 and rs7579 affected the gene 449 
expression of GPX1 and SELENOP. Future nutritional interventions with Brazil nuts 450 
should consider the genetic background of the volunteers when evaluating the 451 
biomarkers of Se status used in this study.   452 
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TABLE 1  
Characteristics of the study volunteers1 
Parameters Total (n= 130) 
Gender, n (%)  
male 32 (24.6) 
female 98 (75.4) 
Age (y), n (%)  
20 – 30y 92 (70.8) 
31 – 40y 20 (15.4) 
41 – 50y 9 (6.9) 
51 – 60y 9 (6.9) 
BMI (kg/m2), n (%)  
< 25 93 (71.5) 
25 – 30 31 (23.8) 
> 30 6 (4.6) 
Smoking status, n (%)  
Never 104 (80.0) 
ex-smoker 20 (5.4) 
current 6 (4.6) 
Physical activity, n (%)  
yes 94 (72.3) 
no 36 (27.7) 
History of chronic diseases, n (%)  
yes 113 (86.9) 
no 17 (13.1) 
Race, n (%)  
caucasian 94 (72.3) 
black 26 (20.0) 
asian/indigen 10 (7.7) 
 Plasma Se (µg/L)  
before supplementation 96.7 ± 29.6 
after supplementation 292.8 ± 95.4 
1 Numerical variables are presented as mean ± standard deviation (sd). Categorical 
variables are presented as n (%).  
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TABLE 2 
 Concentrations of biomarkers1 of Se status during supplementation with Brazil nuts and 
washout period in healthy adults (n = 130) 
Biomarker Supplementation period  
 baseline 4 weeks 8 weeks P value2 
GPx 1 activity 
(U/g Hb) 
61.8 (58.8 – 
65.1)a 
54.4 (52.0 – 
57.1)b 
61.3 (57.7 – 
65.1)a < 0.001 
Erythrocyte Se 
(µg/L) 
169.8 (158.8 – 
181.4)a 
360.2 (342.5 – 
378.9)b 
438.8 (406.6 – 
464.8)c < 0.001 
GPx 3 activity 
(U/L) 
528.1 (510.2 – 
546.6)a 
574.1 (554.4 – 
594.5)b 
544.4 (523.5 – 
566.2)ab   0.004 
Plasma Se (µg/L) 90.7 (86.4 – 
95.2)a 
219.5 (208.4 – 
231.2)b 
267.0 (252.8 – 
282.0)c < 0.001 
SePP (mg/L) 3.4 (3.2 – 3.5)a na 3.9 (3.7 – 4.1)b < 0.001 
Biomarker Washout period  
 8 weeks 4 weeks 8 weeks P value 
GPx 1 activity 
(U/g Hb) 
61.3 (57.7 – 
65.1)a 
68.5 (65.3 – 
71.9)b 
62.8 (58.9 – 
67.0)ab 0.005 
Erythrocyte Se 
(µg/L) 
438.8 (406.6 – 
464.8)a 
484.1 (452.7 – 
517.5)b 
332.1 (307.0 – 
359.3)c < 0.001 
GPx 3 activity 
(U/L) 
544.4 (523.5 – 
566.2)a 
507.1 (486.9 – 
528.2)ab 
480.9 (457.7 – 
505.2)b 0.021 
Plasma Se (µg/L) 267.0 (252.8 – 
282.0)a 
195.3 (186.8 – 
204.2)b 
160.2 (154.3 – 
166.2)c < 0.001 
SePP (mg/L) 3.9 (3.7 – 4.1)a na3 3.5 (3.4 – 3.7)b 0.001 
 
1 Values are geometric means (CI 95%).  
2 ANOVA repeated measures with post hoc Tukey for GPx1 activity; Friedman test 
with post hoc Dunn for Erythrocyte Se, GPx3 activity and Plasma Se; Wilcoxon test for 
SePP concentrations. Different letters in the row mean statistical difference in the time 
points. GPx1 activity and Erythrocyte Se measured in erythrocytes and GPx3 activity, 
Plasma Se and SePP measured in Plasma. GPx, Glutathione Peroxidase; SePP, 
Selenoprotein P. 
3 na: not analyzed 
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TABLE 3  
Genotype and allele frequency of SNPs in selenoprotein genes 
GPX1: Glutathione Peroxidase 1, GPX4: Glutathione Peroxidase 4, SELENOP: Selenoprotein P; 
SELENOF: Selenoprotein 15; SELENOS: Selenoprotein S.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene SNP N CC/GG CT/GA TT/AA alleles MAF HWE 
(p value) 
GPX1 rs1050450 130 53.85 40.77 5.38 C > T T: 0.25 0.560 
 rs3811699 130 53.85 40.77 5.38 C > T T: 0.25 0.560 
 rs1800668 130 53.85 40.77 5.38 C > T T: 0.25 0.560 
GPX4 rs713041 130 38.46 42.31 19.23 C > T T: 0.40 1.914 
SELENOP rs3877899 130 53.85 36.15 10.00 G > A T: 0.28 1.428 
 rs7579 130 38.46 42.31 19.23 G >A T: 0.40 1.914 
SELENOS rs34713741 130 53.85 37.69 8.46 C > T T: 0.27 0.332 
SELENOF rs5845 130 42.31 46.15 11.54 C > T T: 0.35 0.050 
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TABLE 4 
Multiple Linear Regression models for biomarkers of Se status during daily 
supplementation with Brazil nuts and washout period in healthy subjects 
Dependent 
Variables 
Predictors  β coefficient Standard 
error 
P value  
GPx1 activity (U/g Hb)    
Baseline Erythrocyte Se 0.050 0.019 0.011 
4 weeks nuts Erythrocyte Se 0.029 0.012 0.014 
 rs1050450 (GPX1) -5.385 2.546 0.037 
 rs5845 (SELENOF) -7.959 2.605 0.003 
8 weeks nuts rs1050450 -8.300 3.424 0.017 
8 weeks washout rs5845 -8.333 4.189 0.049 
 rs713041 8.955 4.231 0.036 
Erythrocyte Se concentration (µg/L)    
Baseline Plasma Se 1.570 0.215 < 0.001 
 rs713041 (GPX4) -26.698 12.752 0.038 
4 weeks nuts Plasma Se 0.405 0.150 0.008 
8 weeks nuts Plasma Se 0.692 0.158 < 0.001 
Plasma Se concentration (µg/L)    
4 weeks nuts rs7579 (SELENOP) -0.115 0.054 0.034 
 rs34713741 
(SELENOS) 
-0.110 0.053 0.038 
SePP concentration (mg/dL)    
Baseline  Plasma Se 0.007 0.003 0.015 
GPx3 activity 
(U/L) 
    
4 weeks nuts Plasma Se 0.323 0.165 0.050 
8 weeks nuts Plasma Se 0.304 0.134 0.025 
 
1 Multivariate linear regression models were done separately in different time points for 
each biomarker using SPSS. Only significant p values (< 0.05) are shown in the table. 
GPx1 activity and Erythrocyte Se measured in erythrocytes and GPx3 activity, Plasma 
Se and SePP measured in Plasma. GPx, Glutathione Peroxidase; SePP, Selenoprotein P. 
All the models were adjusted for age, gender and body fat percentage. 
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TABLE 5 
Multiple Linear Regression models for the change1 on biomarkers concentrations during 
daily supplementation with Brazil nuts  
 
Dependent Variables Predictors β coefficient 
Standard 
error 
P value  
Change1_GPx1 rs7579 7.372 3.624 0.044 
 
rs5845 54.582 11.334 < 0.001 
Change1_ Erythrocyte Se rs34713741 262.445 100.909 0.010 
 
BMI -11.849 4.348 0.007 
 
gender -107.745 32.802 0.001 
Change1_GPx3 rs5845 -397.353 158.625 0.014 
 
BMI*rs5845 17.412 6.769 0.011 
Change1_ Plasma Se gender -57.110 18.159 0.002 
 
BMI -8.429 2.440 0.001 
Change2_GPx1 gender -40.057 18.162 0.029 
 gender*rs713041 26.269 10.728 0.016 
Change2_SePP rs5845 -3.110 1.521 0.043 
1: Change 1 = (8 weeks nuts) – (baseline) and Change 2 = (8 weeks washout) – (8 weeks nuts) 
All the models were adjusted for age, gender and body fat percentage. GPx, Glutathione Peroxidase; 
SePP, Selenoprotein P. 
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FIGURE 1. Percentage of variation1 in five biomarkers of Se status during and after 
daily supplementation with one unit of Brazil nuts in healthy adults  
 
1 The variation was calculated comparing with the time point immediate before: 4 
weeks nuts compared to baseline, 8 weeks nuts compared to 4 weeks nuts, 4 weeks 
washout compared with 8 weeks nuts and 8 weeks washout compared to 4 weeks 
washout. a) percentage of variation for GPx1 activity, b) percentage of variation for 
Erythrocyte Se, c) percentage of variation for GPx3 activity, d) percentage of variation 
for Plasma Se, e) percentage of variation for SePP.  
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FIGURE 2. Biomarkers of Se status stratified by SNPs in GPX1 and SELENOP genes1. 
1 Values are geometric means ± standard errors. Two way ANOVA repeated measures 
adjusted for multiple comparisons with Bonferroni test. a) Erythrocyte GPx1 activity 
stratified by rs1050450 genotypes, b) Plasma SePP concentration stratified by rs7579 
genotypes.  
 
32 
 
rs1050450 (GPX1)
Before After
0
1
2
3
CC CT+TT
**
a)
G
PX
1 
R
el
at
iv
e 
Ex
pr
es
si
on
 (A
U
)
 
rs3877899 (SELENOP)
Before After
0.0
0.5
1.0
1.5
2.0
GG GA+AA
b)
SE
PP
1 
R
el
at
iv
e 
Ex
pr
es
si
on
 (A
U
)
 
rs7579 (SEPP1)
Before After
0
1
2
3
GG GA+AA
c)
*
*
SE
PP
1 
R
el
at
iv
e 
Ex
pr
es
si
on
 (A
U
)
 
rs34713741(SELENOS)
Before After
0.0
0.5
1.0
1.5
CC CT+TT
d)
SE
LS
 R
el
at
iv
e 
Ex
pr
es
si
on
 (A
U
)
 
rs5845 (SELENOF)
Before After
0.0
0.5
1.0
1.5
2.0
2.5
GG GA+AA
e)
SE
P1
5 
R
el
at
iv
e 
Ex
pr
es
si
on
 (A
U
)
 
 
FIGURE 3. Pattern of selenoprotein gene expression in response to Brazil nut 
supplementation on previously genotyped volunteers1  
1 Gene expression relative to GAPDH a) GPx1 mRNA expression separated by 
rs1050450 genotypes, b) SELENOP mRNA expression separated by rs3877899 
genotypes, c) SELENOP mRNA expression separated by rs7579 genotypes, d) 
SELENOS mRNA expression separated by rs34713741 genotypes, e) SELENOF 
mRNA expression separated by rs5845 genotypes.  
* P < 0.05, Mann-Whitney test, ** P < 0.05, Wilcoxon test 
